Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Dendritic Cells in Hepatitis C Infection

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
University College, London
ClinicalTrials.gov Identifier:
NCT00723242
First received: July 24, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted
  Purpose

The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.


Condition Intervention
Chronic Hepatitis C Infection
Drug: Viraferon-peg and Rebetol

Study Type: Interventional
Study Design: Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by University College, London:

Primary Outcome Measures:
  • Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin) [ Designated as safety issue: No ]

Study Start Date: April 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • anti-HCV positive
  • HCV RNA positive

Exclusion Criteria:

  • contraindications for antiviral treatment
  • concurrent chronic viral infections
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00723242

Locations
United Kingdom
University College Hospital
London, United Kingdom, NW1 2BU
Sponsors and Collaborators
University College, London
Schering-Plough
  More Information

No publications provided

Responsible Party: Professor Nikolai V. Naoumov
ClinicalTrials.gov Identifier: NCT00723242     History of Changes
Other Study ID Numbers: unknown
Study First Received: July 24, 2008
Last Updated: July 24, 2008
Health Authority: United Kingdom: National Health Service

Additional relevant MeSH terms:
Communicable Diseases
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Infection
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 20, 2014